Pfizer’s breast cancer drug, Ibrance’s last-stage trial stopped following excellent performance

April 16, 2015 1:19 PM

11 0

Pfizer on Wednesday said it stopped the ongoing late-stage trial of Ibrance, its newly approved drug for treating breast cancer, because it exceeded expectations in patients who had earlier been treated with estrogen-blocking drug.

The phase 3 study of Ibrance, also known as the Paloma 3, was stopped after an independent data monitory board decided that Ibrance, also known as palbociclib, was excellently effective for breast cancer patients who had had anti-estrogen drug treatments.

Also read: FDA OKs 2nd gene therapy for blood cancer; 1st for adults

Read more

To category page